Investors may gauge a biotech IPO by how much it raised and how much the stock appreciates, but the true measure of success is simple: What did it achieve with the cash? Here, we take a look at biotechs that went public and got a drug to market, as well as those that fizzled after their IPO.
Hear from Moderna’s Chief Digital and Operational Excellence Officer how they have eliminated data siloes to accelerate data-driven decisions at an enterprise level, and established a production environment capable of consistent delivery of complex drug products including a “batch of one”.
Private biotechs raised a record-breaking $16.8 billion in 2018, blowing past the record $12.1 billion set the previous year. Here are the top 10 fundraising rounds—which broke some records themselves and together illustrate what's hot out there in the field.